PHB promotes bladder cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway

Jiang, Lijuan; Guo, Song-Bin; Huang, Zhiye; Li, Xin-Ling; Jin, Xiaojuan; Huang, Weijuan; Tian, Xiao‐Peng

doi:10.1016/j.prp.2023.154536

Cited by 9 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various treatment options, including surgery, radiotherapy and immunotherapy, are available for managing bladder cancer 1 . However, the prognosis of patients with bladder cancer remains unsatisfactory due to recurrence, metastasis and drug resistance 2 . The current standard of care is most effective for individuals with an early‐stage diagnosis of bladder cancer, but patients diagnosed at an advanced stage have limited treatment options.…”

Section: Introductionmentioning

confidence: 99%

“… 1 However, the prognosis of patients with bladder cancer remains unsatisfactory due to recurrence, metastasis and drug resistance. 2 The current standard of care is most effective for individuals with an early‐stage diagnosis of bladder cancer, but patients diagnosed at an advanced stage have limited treatment options. Recognizing the significance of genomic alterations in the development of bladder cancer, 3 it is of utmost importance to extensively investigate the underlying mechanisms of this disease and identify new therapeutic targets.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target

Wang,

Zhang

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

YARS is responsible for catalysing the binding of tyrosine to its cognate tRNA and plays a crucial role in basic biosynthesis. However, its biological functions in bladder cancer remains to be proven. We analysed variations in YARS1 expression and survival in bladder cancer using multiple data sets, including TCGA‐BLCA, GSE13507 and bladder cancer‐specific tissue microarrays. Furthermore, we explored the biological functions of YARS1 using transcriptome data. Our findings revealed a noteworthy correlation between YARS1 and immune infiltration in bladder cancer, as determined using the XCELL algorithm and single‐cell analysis. In addition, we employed the TIDE algorithm to evaluate the responsiveness of different cohorts to immune checkpoint therapy. We investigated the regulatory associations between YARS1 and various aspects of bladder cancer, including senescence, ferroptosis and stemness. Finally, we established a ceRNA network that is directly linked to the overall prognosis, YARS1 can serve as a prognostic biomarker for bladder cancer; its interaction with MYC has implications for bladder cancer cell senescence, ferroptosis and stemness. Moreover, the identified ceRNA network has potential as a therapeutic target in bladder cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target

Wang,

Zhang

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Renal clear cell carcinoma (KIRC), the most common type of renal cell carcinoma, accounts for about 75% of all renal cell carcinomas [4]. Although clear cell carcinoma detected early can be successfully cured surgically, metastasis still occurs in up to 30% of patients, and the prognosis of this metastatic cancer is extremely poor; it seems to be a common problem in urological malignancy [5][6][7]. For these metastatic clear cell carcinomas, systemic therapy based on immunosuppressive agents or targeted drug therapy is an option [8], but their therapeutic efficacy remains limited.…”

Section: Introductionmentioning

confidence: 99%

Construction of exosome-related genes risk model in kidney cell carcinoma predicts prognosis and immune therapy response

Gao,

Huang,

et al. 2024

Aging

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is one of the most prevalent types of urological cancer. Exosomes are vesicles derived from cells and have been found to promote the development of RCC, but the potential biomarker and molecular mechanism of exosomes on RCC remain ambiguous. Here, we first screened differentially expressed exosome-related genes (ERGs) by analyzing The Cancer Genome Atlas (TCGA) database and exoRBase 2.0 database. We then determined prognosis-related ERGs (PRERGs) by univariate Cox regression analysis. Gene Dependency Score (gDS), target development level, and pathway correlation analysis were utilized to examine the importance of PRERGs. Machine learning and lasso-cox regression were utilized to screen and construct a 5-gene risk model. The risk model showed high predictive accuracy for the prognosis of patients and proved to be an independent prognostic factor in three RCC datasets, including TCGA-KIRC, E-MTAB-1980, and TCGA-KIRP datasets. Patients with high-risk scores showed worse outcomes in different clinical subgroups, revealing that the risk score is robust. In addition, we found that immune-related pathways are highly enriched in the high-risk group. Activities of immune cells were distinct in high-/low-risk groups. In independent immune therapeutic cohorts, high-risk patients show worse immune therapy responses. In summary, we identified several exosome-derived genes that might play essential roles in RCC and constructed a 5-gene risk signature to predict the prognosis of RCC and immune therapy response.

show abstract

“…Inappropriate activation of the Wnt pathway has been associated with uncontrolled cell proliferation, invasion, and metastasis in various cancer subtypes. Genistein has a demonstrable ability to interfere with the Wnt pathway through various mechanisms [ [10] , [11] , [12] , [13] ]. One key aspect is its ability to modulate the expression of essential components of the pathway, such as β-catenin.…”

Section: Introductionmentioning

confidence: 99%

Interactions between genistein and Wnt pathway in colon adenocarcinoma and early embryos

Azbazdar,

Sosa,

Monka

et al. 2024

Heliyon

View full text Add to dashboard Cite

PHB promotes bladder cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway

Cited by 9 publications

References 30 publications

Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target

Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target

Construction of exosome-related genes risk model in kidney cell carcinoma predicts prognosis and immune therapy response

Interactions between genistein and Wnt pathway in colon adenocarcinoma and early embryos

Contact Info

Product

Resources

About